Alexandria Real Estate Equities, Inc.'s Consequential Efforts to Address the Mission-Critical Need for Multifaceted Solutions to the Nation's Complex Mental Health Crisis
Alexandria Real Estate Equities (NYSE: ARE) is intensifying its efforts to address the nation's mental health crisis through a multipronged approach. The company is leading a public-private partnership with the Foundation for the National Institutes of Health (FNIH) to develop biomarkers for depression treatment outcomes. Recent progress includes the FDA approval of Karuna Therapeutics' schizophrenia therapy and Intra-Cellular Therapies' potential new depression treatment.
Studies predict that by 2030, the global economic burden of mental health disorders will exceed that of cancer, diabetes, and respiratory diseases combined. ARE's initiatives include investing in innovative companies, advancing partnerships for biomarker development, influencing policy, and supporting organizations like the Navy SEAL Foundation, whose Warrior Fitness Program West Coast facility has helped over 200 active-duty warriors and veterans since late 2023.
Alexandria Real Estate Equities (NYSE: ARE) sta intensificando i suoi sforzi per affrontare la crisi della salute mentale nel paese attraverso un approccio multifaccettato. L'azienda guida una collaborazione pubblico-privata con la Foundation for the National Institutes of Health (FNIH) per sviluppare biomarcatori che valutino i risultati dei trattamenti per la depressione. I progressi recenti includono l'approvazione da parte della FDA della terapia per la schizofrenia di Karuna Therapeutics e il potenziale nuovo trattamento per la depressione di Intra-Cellular Therapies.
Gli studi prevedono che entro il 2030 il peso economico globale dei disturbi mentali supererà quello combinato di cancro, diabete e malattie respiratorie. Le iniziative di ARE comprendono investimenti in aziende innovative, lo sviluppo di partnership per i biomarcatori, l'influenza sulle politiche e il sostegno a organizzazioni come la Navy SEAL Foundation, il cui programma Warrior Fitness Program West Coast ha aiutato oltre 200 guerrieri in servizio attivo e veterani dalla fine del 2023.
Alexandria Real Estate Equities (NYSE: ARE) está intensificando sus esfuerzos para abordar la crisis de salud mental en el país mediante un enfoque multifacético. La empresa lidera una asociación público-privada con la Foundation for the National Institutes of Health (FNIH) para desarrollar biomarcadores que evalúen los resultados del tratamiento de la depresión. Los avances recientes incluyen la aprobación por la FDA de la terapia para la esquizofrenia de Karuna Therapeutics y un posible nuevo tratamiento para la depresión de Intra-Cellular Therapies.
Los estudios pronostican que para el 2030 la carga económica global de los trastornos mentales superará la combinada de cáncer, diabetes y enfermedades respiratorias. Las iniciativas de ARE incluyen invertir en empresas innovadoras, promover asociaciones para el desarrollo de biomarcadores, influir en políticas y apoyar a organizaciones como la Navy SEAL Foundation, cuyo programa Warrior Fitness Program West Coast ha ayudado a más de 200 guerreros en servicio activo y veteranos desde finales de 2023.
Alexandria Real Estate Equities (NYSE: ARE)는 다각적인 접근 방식을 통해 국가의 정신 건강 위기에 대응하기 위한 노력을 강화하고 있습니다. 이 회사는 국립보건원재단(FNIH)과의 공공-민간 파트너십을 주도하여 우울증 치료 결과를 위한 바이오마커를 개발하고 있습니다. 최근 성과로는 Karuna Therapeutics의 조현병 치료제와 Intra-Cellular Therapies의 잠재적 신경 우울증 치료제가 FDA 승인을 받은 점이 있습니다.
연구에 따르면 2030년까지 전 세계 정신 건강 장애의 경제적 부담이 암, 당뇨병, 호흡기 질환을 합친 것보다 더 클 것으로 예상됩니다. ARE의 이니셔티브에는 혁신 기업에 투자하고, 바이오마커 개발을 위한 파트너십을 진전시키며, 정책에 영향력을 행사하고, Navy SEAL Foundation과 같은 단체를 지원하는 것이 포함됩니다. 이 단체의 Warrior Fitness Program West Coast 시설은 2023년 말부터 200명 이상의 현역 군인과 재향군인에게 도움을 제공했습니다.
Alexandria Real Estate Equities (NYSE: ARE) intensifie ses efforts pour répondre à la crise de santé mentale du pays grâce à une approche multiple. L'entreprise dirige un partenariat public-privé avec la Foundation for the National Institutes of Health (FNIH) afin de développer des biomarqueurs pour évaluer les résultats des traitements de la dépression. Les progrès récents incluent l'approbation par la FDA de la thérapie contre la schizophrénie de Karuna Therapeutics et un nouveau traitement potentiel contre la dépression d'Intra-Cellular Therapies.
Les études prévoient qu'en 2030, le fardeau économique mondial des troubles mentaux dépassera celui combiné du cancer, du diabète et des maladies respiratoires. Les initiatives d'ARE comprennent des investissements dans des entreprises innovantes, le développement de partenariats pour les biomarqueurs, l'influence sur les politiques publiques et le soutien à des organisations telles que la Navy SEAL Foundation, dont le Warrior Fitness Program West Coast a aidé plus de 200 combattants en service actif et vétérans depuis fin 2023.
Alexandria Real Estate Equities (NYSE: ARE) verstärkt seine Bemühungen, die psychische Gesundheitskrise des Landes mit einem vielschichtigen Ansatz anzugehen. Das Unternehmen führt eine öffentlich-private Partnerschaft mit der Foundation for the National Institutes of Health (FNIH) an, um Biomarker für Behandlungsergebnisse bei Depressionen zu entwickeln. Zu den jüngsten Fortschritten zählen die FDA-Zulassung der Schizophrenie-Therapie von Karuna Therapeutics und eines potenziellen neuen Depressionstherapies von Intra-Cellular Therapies.
Studien sagen voraus, dass bis 2030 die globale wirtschaftliche Belastung durch psychische Erkrankungen die kombinierte Belastung durch Krebs, Diabetes und Atemwegserkrankungen übersteigen wird. Die Initiativen von ARE umfassen Investitionen in innovative Unternehmen, die Förderung von Partnerschaften zur Biomarker-Entwicklung, Einflussnahme auf politische Entscheidungen und Unterstützung von Organisationen wie der Navy SEAL Foundation, deren Warrior Fitness Program West Coast seit Ende 2023 über 200 aktive Soldaten und Veteranen geholfen hat.
- Partnership with FNIH to develop depression biomarkers for precision psychiatry
- Investment portfolio includes successful companies like Karuna Therapeutics (acquired by Bristol Myers Squibb)
- Contribution to Navy SEAL Foundation's Warrior Fitness Program, supporting over 200 veterans
- Strategic position in advancing mental health solutions through real estate and investments
- Growing global economic burden of mental health disorders expected to surpass cancer, diabetes, and respiratory diseases by 2030
"We are immensely proud of the positive impact and potential of our ongoing endeavors to address our country's staggering mental health crisis. As part of our latest effort, we continue to spearhead the development of a public-private partnership with the Foundation for the National Institutes of Health (FNIH) and leading-edge medicine companies, with the goal of transforming how depression is understood, diagnosed and treated — essentially, laying the groundwork for a new era of precision psychiatry," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "In observance of Mental Health Awareness Month this May, we call for a national public health agenda that prioritizes and spurs innovation in our great country. And we urge continued investment in neuropsychiatric research by the NIH and a well-resourced FDA with efficient and streamlined approval processes for critical diagnostics and therapeutics."
With studies predicting that by 2030 the global economic burden of mental health disorders will surpass that of cancer, diabetes and respiratory diseases, progress in advancing novel medicines for neuropsychiatry is seeing a renaissance. Recent advancements include a first-in-class FDA-approved schizophrenia therapy developed by Karuna Therapeutics, a former Alexandria venture investment company and a recent acquisition by longtime Alexandria tenant Bristol Myers Squibb. Also, in February, the FDA accepted a supplemental new drug application for an adjunctive treatment for adults with major depressive disorder submitted by Alexandria tenant and former investment company Intra-Cellular Therapies, now part of Johnson & Johnson. If approved, this treatment has potential to become a new standard of care for most common depressive disorders.
The mission-critical FNIH public-private partnership aims to develop data-driven measures to identify patient populations that are most likely to meaningfully respond to innovative new treatments for depression. Recognizing that depression is not a single disease, but a complex disorder with a wide range of symptoms, severities and treatment responses, this program takes a precision psychiatry approach and leverages cross-sector expertise and advanced analytics to pave the way for more personalized, effective care tailored to a patient's unique needs.
For more than 15 years, Alexandria has also been partnering with the Navy SEAL Foundation to support its vital mission to provide the nation's elite warriors with physical and mental health resources. Most recently, Alexandria played an instrumental role in establishing and launching the foundation's Warrior Fitness Program West Coast facility in
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the impact of Alexandria's corporate responsibility and thought leadership initiatives, practices, investments and progress, the likelihood of continued support, investment and partnership by Alexandria and the potential impacts of such activities on Alexandria's business and tenants, the companies and non-profit organizations in which Alexandria invests or with which Alexandria has strategic relationships, medicines for mental health disorders and the country's mental health crises. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@are.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-incs-consequential-efforts-to-address-the-mission-critical-need-for-multifaceted-solutions-to-the-nations-complex-mental-health-crisis-302464589.html
SOURCE Alexandria Real Estate Equities, Inc.
FAQ
What is Alexandria Real Estate Equities (ARE) doing to address mental health crisis?
How many veterans has ARE's Navy SEAL Foundation Warrior Fitness Program helped?
What is the expected economic impact of mental health disorders by 2030?
What recent mental health treatment developments are connected to ARE?
What is ARE's partnership with FNIH focused on?
